Dr. Yongxian Hu
✓ Available through China Expert Care
Chief Physician
Bone Marrow Transplantation Center, Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine

Focus: CAR-T cell therapy and allogeneic stem cell transplantation for blood cancers
Dr. Hu works at the Bone Marrow Transplantation Center of the First Affiliated Hospital of Zhejiang University School of Medicine. First author of a New England Journal of Medicine study of sequential CD7 CAR-T therapy and allogeneic stem cell transplantation without graft-versus-host disease prophylaxis (2024), and of a study of CRISPR-engineered universal CD19/CD22 CAR-T cells for B-cell acute lymphoblastic leukaemia.
Conditions: CAR-T cell therapy
Selected publications
- New England Journal of Medicine, 2024 (first author): Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis. PubMed 38657244
- Clinical Cancer Research, 2021 (first author): CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia. PubMed 33627493
Profile on the hospital website: https://www.zy91.com/department/doctor/74/451
Request a written opinion from Dr. Yongxian Hu
Send your records. A medical coordinator will reply within 24 hours.
Start here